beta-3 adrenergic receptor Agonists
3 drugsAbout beta-3 adrenergic receptor
The beta-3 adrenergic receptor (ADRB3) is a G protein-coupled receptor involved in detrusor muscle relaxation. Activation of ADRB3 leads to bladder relaxation. It has relevance in pharmaceutical interventions.
Human genetic studies provide moderate support for ADRB3 as a therapeutic target, with variants linked to peripheral vascular disease (score 0.49) and obesity (score 0.37). Gain-of-function variants appear protective against obesity.
ADRB3 is targeted by 3 FDA-approved small molecule drugs, including MIRABEGRON (MYRBETRIQ). These drugs are marketed by Ascent and APGDI for other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Insulin Resistance with only 1 trials.
- phase3 represents biological uncertainty with 50% completion.
beta-3 adrenergic receptor Genetic Evidence Moderate
Genetic evidence offers moderate support for ADRB3, with a max score of 0.49.
Further investigation of ADRB3's role in peripheral vascular disease may reveal novel therapeutic opportunities.
💡 Why activation?
- • Gain-of-function variants reduce disease risk — enhancing activity may help
- • 100% directional consistency across 1 traits
- • Strong signal in nutritional or metabolic disease, phenotype pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
2 totalGWAS and other genetic studies link ADRB3 to 2 diseases.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top beta-3 adrenergic receptor Drugs
The competitive landscape is relatively concentrated, with only 2 companies holding approved drugs.
The limited number of players suggests a potential opportunity for new entrants in the ADRB3 market.
beta-3 adrenergic receptor Drug Modality Landscape
Modalities
Routes of Administration
beta-3 adrenergic receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
beta-3 adrenergic receptor Clinical Trials 100 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 26 | 24 | 0 | 2 | 100% |
| Phase 2 | 20 | 10 | 2 | 8 | 83% |
| Phase 3 | 21 | 12 | 2 | 7 | 86% |
| Phase 4 | 33 | 21 | 2 | 10 | 91% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved beta-3 adrenergic receptor drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting beta-3 adrenergic receptor. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
beta-3 adrenergic receptor Drug Approval Timeline (2012 - 2021)
The approval timeline spans 10 years, with the first drug approved in 2012 and the most recent in 2021.
The recent approval suggests continued interest in ADRB3, but market saturation should be considered.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 66 clinical trials targeting beta-3 adrenergic receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities